12月11日 - ** 药物开发商 Enliven Therapeutics ELVN.O 股价下跌 1.7%，报 19.82 美元
** Enliven任命 (link) Rick Fair为首席执行官，12月11日生效
** Enliven联合创始人、前首席执行官Sam Kintz将担任新的管线主管，12月11日生效
** Enliven计划于2026年在慢性髓性白血病患者中启动实验药物ELVN-001的后期研究
** 包括盘中走势在内，该股今年累计下跌10.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.